Publications

Read Now

September 2020
Case

Minerva 2010: Turbulent Times

By: John R. Wells and Benjamin Weinstock

In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details

Keywords: Biotechnology; Research; Product Development; Commercialization; Strategy

21 Jun 2018
Video

KPMA HBX Live: Cracking the Data Aggregation Problem - Paul Giusti

October 2021 (Revised February 2022)
Case

Hospital 57357: Aligning Performance Towards a Vision of a Cancer-Free Childhood

By: Susanna Gallani and Youssef Abdel Aal

The case follows the Children Cancer Hospital in Egypt, also known as Hospital 57357, as it goes through the roll-out of a new performance management system, which Dr. Sherif Abouel Naga, founder and CEO of the hospital, had championed. This was a critical juncture as... View Details

Keywords: Healthcare; Performance Management; Performance Incentives; Strategic Alignment; Health Care and Treatment; Nonprofit Organizations; Strategy; Alignment; Performance Evaluation; Mission and Purpose; Change Management; Health Industry; Egypt; Middle East

November 2009 (Revised August 2010)
Case

NovoCure Ltd.

By: William A. Sahlman and Sarah Flaherty

Venture capitalist William Doyle must raise $35 million for a portfolio company with a promising, novel cancer therapy, just as global capital markets are imploding in the fall of 2008. NovoCure, Ltd., has developed an electrical-field-based therapy, called Tumor... View Details

Keywords: Financial Crisis; Entrepreneurship; Venture Capital; Investment; Health Care and Treatment; Health Testing and Trials; Technological Innovation; Financial Services Industry

01 Nov 2010
News

The Mental Game of Breast Cancer: Part Two

10 Jun 2008
First Look

First Look: June 10, 2008

$1.6 billion. The case explores the reasons for the success of this global venture. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=808127 The University of Texas MD Anderson Cancer Center:... View Details

Keywords: Martha Lagace

Genentech Capacity Planning

While facilitating a complex clinical approval process over the next two to three years for a family of new cancer drugs, Genentech must develop a long-term capacity plan for a major class of new cancer products. Adding to the complexity and uncertainty is the fact... View Details

28 Feb 2019
Cold Call Podcast

Pursuing Precision Medicine at Intermountain Healthcare

Keywords: Re: Richard G. Hamermesh; Health; Biotechnology; Pharmaceutical

16 Jun 2020
News

Why Do People Avoid Facts That Could Help Them?

15 Apr 2014
First Look

First Look: April 15

Purchase this case: http://hbr.org/product/pepsico-profits-and-food-the-belt-tightens/an/314055-PDF-ENG Harvard Business School Case 313-012 Cancer Treatment Centers of America® (A) Cancer Treatment Centers... View Details

Keywords: Sean Silverthorne

06 Sep 2006
Lessons from the Classroom

Mixing Students and Scientists in the Classroom

of quantum dots for cancer treatment that had been proposed by an outside sponsor. Along with a bunch of other highly qualified students, one of this team's members was a Dana-Farber Cancer Institute... View Details

Keywords: by Deborah Blagg; Education

20 Sep 2011
First Look

First Look: September 20

on Cancer: Integrative Research Centers at the Dana Farber Cancer Institute Heidi K. Gardner, Edo Bedzra, and Shereef M. ElnahalHarvard Business School Case 412-029 Dr. Barrett Rollins, chief scientific officer of the Dana Farber View Details

Keywords: Sean Silverthorne

March 2018
Case

Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company

By: Rosabeth Moss Kanter and Jonathan Cohen

As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This case follows her career at the company and describes the challenges she faced as a change agent,... View Details

Keywords: Digital; Engagement; Stakeholder Engagement; Grassroots Movement; Organization Change And Adaptation; Quality; Health Care; Health Care Industry; Career Path; Leading Change; Management; Innovation and Management; Personal Development and Career; Organizational Change and Adaptation; Biotechnology Industry; Health Industry

September 2020
Case

Minerva 2020: Clinical Trials

By: John R. Wells and Benjamin Weinstock

In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results... View Details

Keywords: Biotechnology; Strategic Decision Making; Entrepreneurship; Health Testing and Trials; Decision Choices and Conditions; Strategy

21 Jun 2018
Video

KPMA HBX Live Cracking the Data Aggregation Problem - Richard Hamermesh

03 Nov 2011
News

Harvard Business School Professor Paul. R. Lawrence Dies at 89

16 Jul 2021
News

What Ever Happened to IBM’s Watson?

December 2005 (Revised August 2006)
Case

Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

By: Felix Oberholzer-Gee and Dennis A. Yao

Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details

Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States